South African patent for psilocin crystalline forms granted, protection runs to 2043
Entropy Neurodynamics (ASX: ENP) has secured a South African patent covering proprietary crystalline forms of psilocin, expanding its international intellectual property portfolio. The patent, titled “Psilocin Crystalline Forms” (Patent No. 2025/03086), follows the corresponding Australian patent (Patent No. 2023343417) granted earlier in 2026.
The grant strengthens the broader IP position supporting TRP-8803, the company’s proprietary precision-controlled IV psilocin treatment platform. It also covers associated pharmaceutical compositions and methods of preparation.
Key points from the announcement:
- Patent term: 20 years from 12 September 2023, providing protection through to 2043 (September 2043), subject to applicable renewal fees
- Granted patents now span Australia and South Africa
- International applications are progressing across formulations, dosing methods and therapeutic indications
Chief Executive Officer Jason Carroll said the company’s IP strategy is focused on protecting multiple aspects of its proprietary psilocin technology.
Jason Carroll, Chief Executive Officer
“Our IP strategy is focused on building a broad and defensible portfolio that protects multiple aspects of our proprietary psilocin technology, from formulation and delivery through to dosing methodologies and therapeutic applications. By securing protection across these complementary areas, we are seeking to establish meaningful barriers to entry and strengthen our competitive position as we advance TRP-8803 towards commercialisation…”
When big ASX news breaks, our subscribers know first
Why crystalline psilocin forms matter
Psilocin is the active metabolite of psilocybin. A crystalline form is a specific, ordered solid structure of a compound, and it matters in drug manufacturing because stability, solubility and consistency affect how a pharmaceutical-grade product is made and handled.
According to the company, the patented crystalline forms offer improved stability, solubility and consistency compared with conventional psilocin formulations. Entropy says this addresses important considerations in the development and manufacture of pharmaceutical-grade therapeutics.
The patent is distinct from the TRP-8803 platform itself. TRP-8803 is focused on the controlled administration of psilocin, while the newly granted patent protects specific crystalline forms and associated pharmaceutical formulations.
Together, the company says, they cover complementary aspects of psilocin-based drug development, further broadening its IP position across formulation and delivery.
A layered IP portfolio built around TRP-8803
Entropy says the expanding portfolio provides multiple layers of potential IP protection around TRP-8803. The table below summarises the portfolio by jurisdiction as described in the announcement.
| Jurisdiction | Status | Coverage |
|---|---|---|
| Australia | Granted | Precision-controlled IV dosing methodology; psilocin crystalline forms |
| South Africa | Granted | Fibromyalgia treatment methods; crystalline psilocin formulations (this grant) |
| US and other key jurisdictions | Applications progressing | Proprietary formulations, treatment methods, biomarker-guided dosing and indication-specific applications, including Binge Eating Disorder and Irritable Bowel Syndrome |
TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin in Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia.
The earlier South African fibromyalgia patent covers dosing regimens, patient selection, biomarkers and manufacture, and sits in a market independently valued at US$1.9 billion in 2025.
On the commercial side, the company states the expanding portfolio supports its long-term clinical development, commercialisation and strategic partnering objectives. Carroll said the approach also strengthens the company’s position in future licensing and strategic partnership discussions, “while providing the flexibility to pursue opportunities across multiple therapeutic indications.”
Curious About Entropy Neurodynamics’ TRP-8803 Platform and Growing IP Portfolio?
Entropy Neurodynamics has secured a South African patent for proprietary psilocin crystalline forms, with protection running to 2043 and supporting its TRP-8803 precision-controlled IV psilocin platform. With granted patents now spanning Australia and South Africa and further applications progressing, the company is building a layered IP position.
Investors wanting to understand how this strategy underpins its path to commercialisation can visit the Entropy Neurodynamics website for more on its projects and pipeline. It is a useful starting point for assessing the company’s investment potential.